Apotex Recalls Aripiprazole Tablets Due to Dissolution Failures
Apotex Corp. is recalling Aripiprazole Tablets 15 mg because they failed to meet dissolution specifications. The affected products were distributed nationwide in the USA.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically corresponds to a moderate severity score when no specific injuries or hospitalizations are reported in the source text.
Plain-English summary
Apotex Corp. is voluntarily recalling Aripiprazole Tablets, USP 15 mg, packaged in 1000-count and 30-count bottles. The recall is due to the tablets failing to meet required dissolution specifications, which means they may not break down and release the medication as intended.
The affected products are identified by NDC 60505-2675-8 (Lot PZ6716, Exp. 02/2021) and NDC 60505-2675-3 (Lot PZ6715, Exp. 02/2021). A total of 552 bottles of the 1000-count version and 3,192 bottles of the 30-count version were distributed nationwide in the USA.
Consumers and healthcare providers should stop using the recalled tablets and contact their healthcare provider or pharmacist for a replacement or further instructions. The FDA classifies this as a Class II recall, indicating a reasonable probability of temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Aripiprazole Tablets, USP 15 mg tablets, packaged in a) 1000 count bottle, NDC 60505-2675-8; b) 30 count bottle, NDC 60505-2675-3; Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326
- Manufacturer
- Apotex Corp.
- Category
- Drug — Antipsychotic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- a) PZ6716 Exp. 02/2021
- b) PZ6715 Exp. 02/2021
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Apotex Corp.
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateApotek desmopressin nasal spray recalled over dislodged or missing cap liners
FDA (Drugs) · 2026-04-22
- HighBrimonidine and timolol eye drops recalled over sterility assurance failure
FDA (Drugs) · 2026-03-25
- HighKetorolac ophthalmic solution recalled over sterility assurance and bottle sealing concerns
FDA (Drugs) · 2025-10-08
- HighGlaucoma eye drops recalled over sterility assurance and bottle sealing concerns
FDA (Drugs) · 2025-10-08
Same hazard · dissolution failure
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17
- ModerateBelsomra 10 mg tablets failed dissolution, which may delay sleep onset
FDA (Drugs) · 2025-08-20